AMC MCQ Neurology High-Yield Guide for IMGs

Last reviewed: May 2026 | Written by the MplusX Editorial Team

---

---

Neurology accounts for approximately 8–10% of the AMC MCQ blueprint.

That percentage is deceptive. Neurological presentations — stroke, seizure, headache, and cognitive decline — appear embedded inside emergency medicine, internal medicine, and paediatrics questions too.

A candidate who does not command neurology will bleed marks across multiple domains simultaneously.

This guide maps every high-yield neurology topic, walks through the key clinical decision rules, and deconstructs five classic distractor traps the examiner sets for underprepared candidates.

---

1. The AMC MCQ Neurology Blueprint

Before drilling topics, understand what the examiner prioritises.

Across recent AMC MCQ sittings, neurology questions cluster into five distinct zones:

Topic Area	Approximate Frequency	Most Tested Decision Point
Stroke and TIA	Very high	tPA eligibility, CT timing, anticoagulation rules
Seizure and epilepsy	High	Status epilepticus protocol, drug selection
Headache disorders	High	SAH red flags, migraine vs. tension differentiation
Dementia and cognition	Moderate	Diagnostic workup, MMSE vs. MoCA
Parkinson’s disease	Moderate	Levodopa initiation, driving restrictions
Multiple sclerosis	Moderate	McDonald Criteria, DMT eligibility
Peripheral neuropathy and GBS	Lower	IVIG criteria, respiratory monitoring

Study the top three rows with clinical-depth precision.

Study the bottom four rows with recognition-level precision.

---

2. Stroke and TIA

2.1 Ischaemic Stroke: The tPA Decision

The intravenous thrombolysis decision is the most tested moment in all AMC MCQ neurology.

The drug is alteplase (tPA). The window is 4.5 hours from last-known-well time.

Inclusion Criteria (all must be present)

• Clinical diagnosis of ischaemic stroke causing measurable neurological deficit
• Symptom onset (or last-known-well) within 4.5 hours
• Age ≥ 18 years
• CT brain confirms no haemorrhage

Absolute Exclusion Criteria (any one rules out tPA)

Criterion	Clinical Rationale
CT showing haemorrhage	Cannot thrombolyse a bleed
BP > 185/110 mmHg (untreated)	Must lower BP first; if refractory, withhold tPA
Blood glucose < 2.8 or > 22.0 mmol/L	Rule out hypoglycaemia as stroke mimic
Active internal bleeding	Obvious contraindication
INR > 1.7 (warfarin use)	Excessive bleeding risk
Platelet count < 100 × 10⁹/L	Clotting capacity insufficient
DOAC within last 48 hours	Must check coagulation studies
Major surgery or serious trauma within 14 days	Bleed risk
Previous intracranial haemorrhage	Absolute
Ischaemic stroke within 3 months	Relative exclusion

The AMC MCQ will present a patient who appears to qualify — and then embed one silent exclusion criterion. Read every demographic detail and every medication listed in the stem.

CT Timing Rule

Non-contrast CT brain must occur before any thrombolysis decision.

You are ruling out haemorrhagic stroke. A normal CT in the first 24 hours does not exclude ischaemic stroke — it merely excludes haemorrhage.

If the CT shows a dense middle cerebral artery (MCA) sign — a hyperdense MCA on non-contrast CT — this suggests a large vessel occlusion. Endovascular thrombectomy (EVT) becomes a consideration. Reading about best AMC MCQ resources might also be helpful.

2.2 TIA Management

The AMC MCQ treats TIA as a medical emergency, not a “watchful waiting” scenario.

The ABCD2 score risk-stratifies TIA. However, in 2026 Australian clinical practice (per eTG and RACGP), the more useful tool is recognising that high-risk TIA requires same-day specialist assessment and investigation, not wait-and-see.

Immediate antiplatelet therapy following TIA (per eTG 2026):

• Aspirin 300 mg orally immediately (loading dose), then 100 mg daily
• Clopidogrel 300 mg loading dose added for dual antiplatelet therapy in non-cardioembolic TIA for the first 21 days — this reflects the 2022–2026 updated POINT trial-influenced guidance

Cardioembolic TIA (atrial fibrillation as source):

• Do NOT add clopidogrel
• Initiate oral anticoagulation — DOAC (apixaban or rivaroxaban preferred) once haemorrhage excluded
• Timing of anticoagulation initiation after TIA: within 24–48 hours is safe if CT confirms no haemorrhage

The examiner will test whether you know the difference between non-cardioembolic (dual antiplatelet) and cardioembolic (anticoagulation) TIA management. These are common distractor setups.

2.3 Antiplatelet vs. Anticoagulation Post-Stroke

After confirmed ischaemic stroke:

• Aspirin 300 mg within 24–48 hours if tPA not given
• If tPA was given: delay antiplatelet therapy for 24 hours post-thrombolysis

For atrial fibrillation-related ischaemic stroke:

• Initiate anticoagulation (not antiplatelet) — timing guided by stroke severity
• Minor stroke (NIHSS < 8): anticoagulation within 24–48 hours
• Moderate stroke (NIHSS 8–15): anticoagulation at 6–7 days
• Severe stroke (NIHSS > 15): anticoagulation at 12–14 days

These timing windows are live AMC MCQ exam content.

---

3. Seizure Management

3.1 First Unprovoked Seizure

The AMC MCQ tests first-seizure management at the TOFU level.

Immediate steps: 1. Safety — position, do not restrain, protect airway 2. Blood glucose (BGL) — exclude hypoglycaemia immediately 3. Sodium — hyponatraemia is the most common metabolic seizure trigger Reading about AMC MCQ recalls might also be helpful. 4. Assess for structural cause — CT/MRI brain 5. EEG — not in the acute phase; performed within 24–48 hours outpatient

To start antiepileptic drugs (AEDs) or not: A single unprovoked seizure in an adult with a normal EEG and normal MRI does not necessarily require AED therapy. The decision is shared with the patient based on recurrence risk.

Two seizures = start AEDs. The AMC MCQ will test this threshold.

3.2 Status Epilepticus Protocol

Status epilepticus (SE) is defined as: seizure activity lasting > 5 minutes, OR two or more discrete seizures between which the patient does not return to baseline.

This is a neurological emergency. The AMC MCQ tests your sequential, time-critical protocol.

The eTG 2026-aligned SE Protocol:

Phase	Time Point	Drug	Dose
Phase 1 (Benzodiazepine)	0–5 min	IV lorazepam	0.1 mg/kg (max 4 mg) — repeat once if seizure continues at 5 min
Phase 1 alternative	If no IV access	Midazolam (buccal or IM)	0.3 mg/kg (max 10 mg)
Phase 2 (Second-line AED)	10–20 min	IV levetiracetam	60 mg/kg (max 4,500 mg) over 15 min
Phase 2 alternative		IV sodium valproate	40 mg/kg (max 3,000 mg) over 15 min
Phase 3 (Refractory SE)	> 30–45 min	ICU intubation + anaesthetic agents	Propofol or midazolam infusion

Note: Phenytoin is no longer first-line in Australian guidelines (eTG 2026). Levetiracetam has replaced it. This is a high-yield distractor: the exam will offer phenytoin as an option — it is the wrong answer.

---

---

3.3 Driving Restrictions After Seizure in Australia

Per AUSTROADS/AHPRA-aligned Medical Standards for Fitness to Drive (2026 edition):

• Private vehicle licence: 12 months seizure-free before resuming driving
• Commercial vehicle licence: 5 years seizure-free (bus, truck, taxi)

This is a legally mandated discussion you must have with the patient. The AMC MCQ will present a vignette where the patient asks about driving. The correct answer involves counselling, documentation, and advising the mandatory reporting pathway per state law.

---

4. Headache Disorders

4.1 Subarachnoid Haemorrhage — The “Worst Headache of My Life”

The single most tested headache scenario in AMC MCQ.

Presentation: Sudden onset, severe, “thunderclap” headache reaching maximum intensity within seconds. May be accompanied by neck stiffness, photophobia, or loss of consciousness.

Immediate investigation: Non-contrast CT brain — sensitivity is approximately 98% within 6 hours of onset.

If CT is negative but SAH is strongly suspected: Lumbar puncture at > 12 hours from symptom onset, looking for:

• Xanthochromia (yellow discolouration of CSF) — more sensitive than red cells
• Red blood cells in CSF that do not decrease between tubes 1 and 4

Management: Urgent neurosurgical referral. Nimodipine 60 mg orally every 4 hours (cerebral vasospasm prevention). Avoid hypotension.

The AMC MCQ will offer the diagnosis of tension headache or migraine as attractive distractors. The clinical clue is thunderclap onset and “worst ever” quality. Neither tension nor migraine presents that way.

4.2 Migraine Management

Acute treatment (per eTG 2026):

• First-line: NSAIDs (ibuprofen 400–600 mg) or paracetamol 1g + metoclopramide 10 mg (antiemetic and enhances absorption)
• Second-line: Triptans (sumatriptan 50–100 mg orally, or 6 mg subcutaneous for rapid onset)
• Triptan contraindications: Ischaemic heart disease, previous stroke/TIA, uncontrolled hypertension, hemiplegic migraine

Prophylaxis (if ≥ 4 migraine days/month):

• Topiramate, amitriptyline (low dose), propranolol, or metoprolol
• CGRP monoclonal antibodies (erenumab, fremanezumab) — available under PBS for refractory migraine in Australia since 2021

4.3 Cluster Headache

Cluster headache presents as unilateral orbital or periorbital pain, severe, 15–180 minutes duration, occurring in clusters (multiple times per day for weeks to months).

Key features distinguishing it from migraine:

• Male predominance (unlike migraine)
• Autonomic features: ipsilateral lacrimation, nasal congestion, ptosis, conjunctival injection
• Patient is restless and agitated (migraine patients prefer to lie still)

Acute treatment: High-flow oxygen (100% O₂ via non-rebreather mask for 15 minutes) — this is the AMC-tested first-line. Subcutaneous sumatriptan is equally effective.

---

5. Dementia and Cognitive Decline

5.1 Diagnostic Workup in Australian Primary Care

The RACGP recommends a structured approach to cognitive complaint in primary care.

Cognitive screening tools:

• MMSE (Mini-Mental State Examination): Score out of 30. Widely used but less sensitive for early decline. Score < 24 suggests dementia.
• MoCA (Montreal Cognitive Assessment): Score out of 30. More sensitive for mild cognitive impairment. Score < 26 suggests impairment.

The AMC MCQ prefers MoCA for patients with higher educational attainment and milder presentations.

Reversible causes to exclude before diagnosing dementia:

Investigation	What It Excludes
TFTs	Hypothyroidism
B12 and folate	Nutritional deficiency
FBC	Anaemia
EUC	Metabolic cause
LFTs	Hepatic encephalopathy
Blood glucose	Diabetes-related
VDRL/RPR	Neurosyphilis (in risk groups)
CT or MRI brain	Normal pressure hydrocephalus, subdural haematoma, tumour

5.2 Dementia Subtypes

Type	Key Distinguishing Feature	AMC-Tested Point
Alzheimer’s disease	Insidious onset, progressive memory loss	Cholinesterase inhibitor (donepezil) — symptom control only, not curative
Vascular dementia	Stepwise decline, vascular risk factors	Treat underlying CVD risk factors
Lewy body dementia	Visual hallucinations + Parkinsonism + fluctuating cognition	Avoid antipsychotics (severe sensitivity reaction)
Frontotemporal dementia	Behavioural change before memory loss	Younger onset; no approved pharmacotherapy

Lewy body dementia is a high-yield distractor trap. The AMC MCQ will present a patient with dementia who also has Parkinsonism and visual hallucinations, and will offer antipsychotics (e.g., haloperidol, olanzapine) as management options. These are dangerous in Lewy body disease and are the wrong answer.

---

6. Multiple Sclerosis

6.1 Diagnosis — McDonald Criteria 2017

MS diagnosis requires demonstration of dissemination in space (DIS) and dissemination in time (DIT) — meaning lesions in multiple CNS locations and evidence of lesion accumulation over time.

MRI findings:

• Periventricular, juxtacortical, or infratentorial T2/FLAIR hyperintense lesions
• Gadolinium-enhancing lesions represent active inflammation

CSF analysis:

• Oligoclonal bands (absent in serum but present in CSF) — supportive but not required for diagnosis if MRI criteria met

6.2 Disease-Modifying Therapies (DMTs) in Australia

DMTs are PBS-funded for relapsing-remitting MS.

First-line DMTs (oral):

• Dimethyl fumarate (Tecfidera)
• Teriflunomide (Aubagio)

Second-line/high-efficacy DMTs:

• Natalizumab — requires JC virus antibody testing before initiation (PML risk)
• Ocrelizumab — B-cell depleting, also approved for primary progressive MS
• Cladribine — oral pulsed therapy

The AMC MCQ tests the principle: first relapse does not automatically require DMT. Patients with high-risk features (incomplete recovery, multiple lesions) are started earlier. Low-risk CIS (clinically isolated syndrome) may be monitored.

6.3 Acute Relapse Management

IV methylprednisolone 1 g/day for 3–5 days — per eTG 2026.

Speeds recovery from relapse but does not change long-term disability trajectory. This distinction is an AMC MCQ favourite.

---

7. Parkinson’s Disease

7.1 Diagnosis

Parkinson’s disease is a clinical diagnosis based on the UKPDS Brain Bank Criteria:

• Bradykinesia (mandatory)
• Plus one of: resting tremor, rigidity, or postural instability

Red flags that suggest an alternative diagnosis (Parkinson’s-plus syndromes):

• Early falls (PSP — progressive supranuclear palsy)
• Early autonomic failure (MSA — multiple system atrophy)
• Asymmetric apraxia (CBS — corticobasal syndrome)
• Severe early dementia (Lewy body dementia)

7.2 Pharmacological Management

Levodopa + carbidopa (Sinemet):

• Most effective symptomatic treatment at any stage
• Carbidopa prevents peripheral conversion of levodopa to dopamine (reduces nausea, allows more levodopa to cross blood-brain barrier)
• Long-term complication: dyskinesia and “wearing off” phenomenon

Dopamine agonists (pramipexole, ropinirole):

• Less effective than levodopa but fewer motor complications in early disease
• Impulse control disorders (gambling, hypersexuality, binge eating) are a recognised side effect — the AMC MCQ will test this

MAO-B inhibitors (selegiline, rasagiline):

• Mild symptomatic benefit, possible neuroprotective role
• Drug interaction: do not combine with SSRIs or pethidine (risk of serotonin syndrome)

7.3 Driving Restrictions in Parkinson’s Disease

Per AUSTROADS Medical Standards for Fitness to Drive (2026):

• Private licence: Assessed individually; requires notification to licensing authority. Annual medical review. Clinical signs of sufficient severity to impair driving are disqualifying.
• Commercial licence: Parkinson’s disease is disqualifying for commercial vehicle licences.

The AHPRA-aligned fitness-to-drive framework requires clinicians to advise patients of their legal obligation to notify the licencing authority. Failure to counsel this is a medicolegal error and an AMC MCQ wrong-answer trap.

---

8. Peripheral Neuropathy and Guillain-Barré Syndrome

8.1 Guillain-Barré Syndrome (GBS)

Classic presentation:

• Ascending symmetrical weakness beginning in the legs
• Areflexia (hallmark)
• Onset 2–4 weeks after an infective illness (Campylobacter jejuni is the most common antecedent infection)
• Autonomic dysfunction (HR variability, BP fluctuation)
• Respiratory compromise in severe cases

Critical investigation: Serial FVC (forced vital capacity).

Intubation threshold: FVC < 15–20 mL/kg, or rapid decline of > 30% in FVC over 24 hours, or inability to count to 20 in a single breath.

Treatment:

• IVIG (IV immunoglobulin) 0.4 g/kg/day for 5 days — first-line in Australia
• Plasmapheresis — equally effective alternative, less commonly available
• NOT corticosteroids — steroids do not improve GBS outcomes and may worsen them; this is a high-yield distractor

8.2 Other Common Neuropathies

Neuropathy Type	Cause	Key Clinical Feature
Diabetic peripheral neuropathy	Chronic hyperglycaemia	Length-dependent, stocking-glove, burning at night
Carpal tunnel syndrome	Median nerve compression	Thenar wasting, Tinel’s, Phalen’s sign
Ulnar neuropathy	Elbow compression	Claw hand (ring and little finger), weak hypothenar
Common peroneal nerve palsy	Fibular head compression	Foot drop, loss of dorsiflexion and eversion
B12 deficiency (subacute combined degeneration)	Posterior and lateral column involvement	Neuropathy + upper motor neurone signs simultaneously

---

9. High-Yield Distractor Deconstruction

Five clinical scenarios where the AMC MCQ examiner sets the trap.

Scenario 1 — The Stroke Mimic

A 52-year-old woman presents with sudden right-arm weakness and dysarthria. Last seen normal 2.5 hours ago. CT brain is normal. BGL is 1.9 mmol/L. What is the next best management step?

Trap: administer tPA immediately.

Correct answer: Give IV dextrose immediately. Hypoglycaemia is a stroke mimic that must be excluded before thrombolysis. BGL < 2.8 mmol/L is an absolute exclusion criterion for tPA.

Scenario 2 — The Seizure Drug Selection

A 68-year-old man is actively seizing. IV access is obtained. He has received lorazepam 4 mg IV with no response. What is the next drug?

Trap: phenytoin 20 mg/kg IV.

Correct answer: Levetiracetam 60 mg/kg IV (max 4,500 mg). Phenytoin is no longer first-line in the eTG 2026 status epilepticus protocol.

Scenario 3 — The Headache That Isn’t Migraine

A 41-year-old lawyer presents with sudden onset headache that reached maximum intensity in under 30 seconds. She rates it 10/10. She has had migraines before — this feels different. CT brain is normal. What do you do next?

Trap: discharge with migraine management and follow up in 2 weeks.

Correct answer: Lumbar puncture at > 12 hours from onset to look for xanthochromia. A normal CT does not exclude SAH within the first 6–12 hours.

Scenario 4 — Lewy Body Trap

A 76-year-old man has progressive memory loss with visual hallucinations and a resting tremor. His family reports fluctuating periods where he seems confused and then quite lucid. He becomes agitated on the ward. What medication is most appropriate?

Trap: haloperidol 2 mg IMI.

Correct answer: Low-dose clonazepam or avoid antipsychotics entirely. This is Lewy body dementia. Typical antipsychotics (and many atypicals) cause severe neuroleptic sensitivity reactions, worsening rigidity and potentially inducing a neuroleptic malignant syndrome-like state.

Scenario 5 — The GBS Steroid Trap

A 28-year-old man presents with 3-day history of progressive leg weakness and absent ankle reflexes, 3 weeks after a diarrhoeal illness. What treatment do you initiate?

Trap: oral prednisolone.

Correct answer: IVIG 0.4 g/kg/day for 5 days. Steroids are not effective in GBS and may be harmful. This is one of the most reliably tested pharmacological counterintuitives in AMC MCQ neurology.

---

10. Building Your Neurology Exam Strategy

Triage Neurology Preparation into Two Tiers

Tier 1 (spend 70% of neurology study time here):

• Ischaemic stroke — tPA criteria, CT timing, antiplatelet vs. anticoagulation
• Status epilepticus protocol — sequential drug escalation
• Subarachnoid haemorrhage — thunderclap headache workup
• GBS — FVC monitoring, IVIG, no steroids

Tier 2 (spend 30% of neurology study time here):

• Parkinson’s — levodopa initiation, dopamine agonist side effects, driving rules
• MS — McDonald Criteria, DMT principles
• Dementia — Lewy body trap, reversible causes workup
• Peripheral neuropathy — pattern recognition by anatomy

QBank Drilling Tip

Filter your MplusX QBank specifically to Neurology category and set it to timed mode with show explanations after each block disabled.

Complete 25–30 questions. Then review all explanations in bulk.

The time pressure forces you to practise the 85-second-per-question AMC exam pacing. The bulk explanation review forces you to engage with the reasoning rather than passively confirm your correct answers.

---

---

Frequently Asked Questions

How many neurology questions are on the AMC MCQ?

Neurology accounts for approximately 8–10% of the 150-question paper, equating to roughly 12–15 dedicated questions. Additional neurology-adjacent content appears within emergency medicine and paediatrics sections.

Is ischaemic stroke always the highest-yield neurology topic?

Across multiple sitting cycles, stroke and seizure management have been the most frequently tested neurological topics. Headache (particularly SAH) is close behind. Candidates who master these three topics will capture the majority of neurology marks.

Do I need to know the NIHSS scoring system for AMC MCQ?

You do not need to score a patient using NIHSS numerically. You do need to know that NIHSS guides anticoagulation timing after ischaemic stroke in the setting of atrial fibrillation, and that higher NIHSS scores delay anticoagulation initiation. Reading about MplusX vs AMEDEX might also be helpful.

Is phenytoin ever used in Australian emergency practice?

Phenytoin is still used in some centres. However, the eTG 2026 protocol positions levetiracetam and sodium valproate as first-choice second-line AEDs. In an AMC MCQ context, selecting levetiracetam over phenytoin reflects current Australian standard-of-care.

What is the MoCA cutoff for diagnosing MCI?

A MoCA score < 26/30 suggests mild cognitive impairment. A score < 18 typically indicates moderate dementia. These thresholds are used in Australian primary care settings.

---

Start Drilling Neurology Today

Neurology rewards systematic preparation.

The distractor traps in AMC MCQ neurology questions are not random. They are predictable. The tPA stroke mimic, the phenytoin seizure trap, the SAH lumbar puncture step, the GBS steroid trap — these appear because they represent genuine clinical decision points where dangerous errors occur.

Study the clinical reasoning, not just the answer.

See the Full MplusX Subject Series — access guided neurology category sessions with eTG-aligned explanations and track your domain accuracy across all five neurology subtopics in one dashboard.

---

Written by the MplusX Editorial Team — dedicated to providing clinically accurate, structured, and practical resources for international medical graduates pursuing licensing with the Australian Medical Council.

References

• John Murtagh‘s General Practice (8th Edition): Chapter 22: Neurological dilemmas, Page 531; Chapter 35: Dizziness/vertigo, Page 1044; Chapter 45: Headache, Page 1296; Chapter 121: Stroke and transient ischaemic attacks, Page 3202
• RACGP Red Book (10th edition): Chapter 5.5: Dementia, Page 51; Chapter 8.5: Stroke, Page 94
• Therapeutic Guidelines (eTG): Part 2 Neurology: Chapter 1: Acute management of seizures and status epilepticus, Page 695; Chapter 43: Stroke and transient ischaemic attack, Page 805

---

Disclaimer: This article is written for AMC MCQ examination preparation and general informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Clinical decisions should always be based on individual patient assessment, current Australian Therapeutic Guidelines (eTG), and consultation with qualified healthcare professionals. MplusX is an exam preparation platform and is not a substitute for supervised clinical training.